PPAR-δ agonist that boosts endurance and fat oxidation — not a SARM but commonly grouped here.
Typical dose range: 10–20 mg
Frequency: Daily
Route: Oral
Half-life: ~24 h
Evidence level: Pre-clinical (cancer flag)
Trials were halted due to rodent cancer signal at very high doses — community use is at much lower doses but the data is unresolved.